Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction

This study has been completed.
Helse Stavanger HF
Information provided by (Responsible Party):
Lars Gullestad, Oslo University Hospital Identifier:
First received: February 1, 2007
Last updated: January 24, 2014
Last verified: January 2014
The instigators hypothesize that IVIG, given in the acute phase following MI in patients at risk for developing HF, will improve cardiac performance, and by attenuating cardiac remodeling in this phase, such therapy will prevent the development of chronic HF resulting in long term beneficial effect also after the therapy has been stopped.

Condition Intervention Phase
Acute Myocardial Infarction
Drug: Octagam (IVIG)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase III Study of Intravenous Immunglobulin (IVIG) in Patients With Heart Failure After Myocardial Infarction

Resource links provided by NLM:

Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • 1. The effect on IVIG on LV remodeling (volume and ejection fraction) and function as assessed by MRI [ Time Frame: 2009 ]

Secondary Outcome Measures:
  • 2. Effect on IVIG on B-Type Natriuretic Peptide (BNP). [ Time Frame: 2009 ]

Enrollment: 62
Study Start Date: February 2007
Study Completion Date: May 2010
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Saline Drug: Octagam (IVIG)
Intravenous immunoglobulin 0.4 g/kg given as infusion
Other Name: Intravenous immunoglobulin 0.4 g/kg given as infusion
Experimental: Octagam (IVIG)
Octagam (IVIg) is intravenous immunglobulin
Drug: Octagam (IVIG)
Intravenous immunoglobulin 0.4 g/kg given as infusion
Other Name: Intravenous immunoglobulin 0.4 g/kg given as infusion

Detailed Description:

This double-blind placebo-controlled study represents a new approach to cardiovascular disease. The project deals with unresolved issues in the intersection between cardiology, immunology and molecular biology.

IVIG/placebo will be given as an induction therapy for 5 days and thereafter as monthly infusions for 5 months. Change in left ventricular remodeling will be assessed at baseline, and 6 and 12 months with MRI and echocardiography.

The objectives are:

  1. The primary objective of this study is to evaluate the effect on IVIG on LV remodeling and function: LV remodeling will be evaluated with magnetic resonance imaging (MRI) which offers an unsurpassed precision in the measurements of heart volumes and function. End points will be LV-end systolic and diastolic volume (LVESV, LVEDV), regional wall motion score index (WMSI), and LV-ejection fraction (LV-EF).
  2. The secondary objective of this study is to evaluate the effect on IVIG on the myocardial marker B-Type Natriuretic Peptide (BNP). BNP is a sensitive marker of the degree of HF besides being a prognostic indicator 18-20.
  3. The tertiary objective of this study is to evaluate the effect on IVIG on:

    a. Quality of life. b. Effect on New York Heart Association (NYHA) functional class. c. Effect on immunological variables. i. Inflammatory cytokines such as TNF-alpha, IL-6, IL-18. ii. Anti-inflammatory cytokines such as IL-10 and transforming growth factor beta iii. Chemokines such as monocyte chemoattractant protein 1, IL-8 and CCL21. iv. Regulators of hypertrophy such as matrix metalloproteinases, their endogenous inhibitors (i.e., TIMPs) and procollagen III N-terminal.

    d. Effect on neurohormones. e. Withdrawals. f. Side effects.


Ages Eligible for Study:   18 Years to 18 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age of 18-80 years
  • Have a recent MI (<5days)
  • Have ASAT >100 U/L or CKMB > 50 U/L.
  • Have LVEF <40%.
  • Are on optimal medical treatment and considered unsuitable for surgical intervention.

Exclusion Criteria:

  • Evidence of unstable disease, concomitant ischemia or unstable angina during the hospitalization.
  • Significant concomitant disease such as infections, pulmonary disease or connective tissue disease.
  • Participating in other studies.
  • Inability to participate.
  • Diseases that require surgery.
  • Planned revascularisation.
  • Known hypersensitivity to IVIG.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00430885

Rikshospitalet University Hospital
Oslo, Norway
Sponsors and Collaborators
Oslo University Hospital
Helse Stavanger HF
Principal Investigator: Lars Gullestad, MD, PhD
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Lars Gullestad, Professor, Oslo University Hospital Identifier: NCT00430885     History of Changes
Other Study ID Numbers: 175464/V50
NFR 175464/V50
Study First Received: February 1, 2007
Last Updated: January 24, 2014

Keywords provided by Oslo University Hospital:
Heart failure
Myocardial infarction
Patients with acute myocardial infarction

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017